US neutraceutical giant bullish on Phl market

An American neutraceutical giant is projecting the rise of its breakthrough health products to the top of the heap in the Philippines’ direct selling food supplement market.

Acknowledging the Philippines’ global position as the second biggest market after the United States or the largest outside the continental North America for food supplement Laminine, visiting LifePharm Global Network (LPGN) vice president and chief finance officer Wickson Suyanto said the brand also appeared going tops locally on the strength of its uniqueness and the aggressive marketing push by exclusive national distributor Forever Rich Philippines Inc. (FRPI)

Suyanto said LPGN, through FRPI, “wants to be here (Philippines) for the long term” as he assured the company’s network marketers of security and stability in the conglomerate’s global operations.

“Just this year alone, LPGN has opened up four new countries (Australia, Russia, Ukraine, and Singapore) for Laminine,” Suyanto said.

The four new countries bring Laminine’s global market coverage to nine, together with the US, Canada, Korea, Indonesia and the Philippines.

Of the nine, US, Canada, Australia and Singapore have substantial populations of migrant Filipinos, putting FRPI at the forefront of LPGN’s expansion, particularly in Asia.

In effect, FRPI’s Filipino and foreign members in those countries can now order products direct from LPGN and have them credited in their names and those of their uplines in the Philippines, making all earn dollar commissions in the process.

Suyanto said these developments were driven by LPGN’s pursuit of excellence and strong belief in quality that “makes a lot of difference” in the market.

“My dad (LPGN chief executive officer Wicky Suyanto) is a firm believer in quality products. We do countless clinical studies before we even think of putting anything out on the market. In fact, I’m like the guinea pig,” the young Suyanto said, revealing how he and his family would first try the product and test it on themselves after conclusive studies.

There are many consumer products being produced and manufactured by LPGN mother firm LifePharm Inc., but only Laminine and the new Laminine Omega Triple Plus are being distributed globally via networking, or multi-level marketing.

Laminine consists largely of fibroblast growth factors that make the body produce the type of cells it needs to remain young, normal and healthy, especially when under stress or encumbered by diseases.

This breakthrough product has just given birth to a variant called Laminine Omega Triple Plus, which is specifically formulated to address the rise in cardiovascular diseases, the leading cause of death in the US, the Philippines, and many other countries.

The product was launched at the Music Museum by Suyanto and FRPI chief executive officer Susan Barlin, with LPGN product research specialist Dr. Edward Andujar leading the guests from the scientific community and the medical profession.

A Harvard-educated medical research scientist, Andujar warned that mankind had arrived at a point where every person could be genetically or environmentally predisposed to cardio-vascular diseases as a result of the world’s lifestyle.

This global health situation, according to Andujar, necessitated the product research, development and clinical studies that created the Laminine Omega Triple Plus.

Andujar further warned that with today’s lifestyle, a person’s blood vessels could become 50 percent clogged at age 21, and completely blocked at age 50.

“If the trend continues, all of us will have to eventually undergo heart bypass, which costs $60,000 in the US,” Andujar said in stressing the mission of Omega Triple Plus.

The product contains omega 3, 6 and 9 fatty acids that increase the good cholesterol in the blood, the powerful antioxidant co-enzyme Q10 that lowers blood pressure, and the vitamin K2 that prevents calcium deposits in the blood vessels and puts them instead in the bones and teeth where they should be.